Bristol-Myers’ Rosy Outlook Trumps Trial Setback as Stock Gains

(Bloomberg) -- Bristol-Myers Squibb Co. acknowledged that its top-selling cancer drug faces challenges in coming years, one day after reporting a clinical setback that caused the drugmaker’s shares...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.